Lunsumio® (mosunetuzumab) could be the first CD20xCD3 T-cell engaging bispecific antibody approved by the FDA for the treatment of any type of non-Hodgkin lymphoma Application is based on results from the pivotal phase I/II study...

Exploring New Methods & Imaging Technologies for Cancer Immunotherapy Research Pathology Imaging User Group Meeting October 22-23, 2014 Erasmus University Medical Centre Bldg Ae, Rm 406 Rotterdam, The Netherlands   Reserve...